In recent trading session, ImmunityBio Inc (NASDAQ:IBRX) saw 3.05 million shares changing hands at last check today with its beta currently measuring 0.70. Company’s recent per share price level of $3.70 trading at -$0.2 or -5.20% at last check today assigns it a market valuation of $2.70B. That most recent trading price of IBRX’s stock is at a discount of -184.59% from its 52-week high price of $10.53 and is indicating a premium of 38.38% from its 52-week low price of $2.28.
For ImmunityBio Inc (IBRX), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Upright in the red during last session for losing -5.20%, in the last five days IBRX remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $3.70 price level, adding 13.35% to its value on the day. ImmunityBio Inc’s shares saw a change of 44.42% in year-to-date performance and have moved 14.11% in past 5-day. ImmunityBio Inc (NASDAQ:IBRX) showed a performance of 14.82% in past 30-days.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 38.33% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -62.16% in reaching the projected high whereas dropping to the targeted low would mean a loss of -62.16% for stock’s current value.
ImmunityBio Inc (IBRX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.17% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 30.43% while estimates for its earnings growth in next 5 years are of 32.58%.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
VANGUARD GROUP INC is the top institutional holder at IBRX for having 13.83 million shares of worth $87.42 million. And as of 2024-06-30, it was holding 2.0558 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 11.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6978 of outstanding shares, having a total worth of $72.19 million.
On the other hand, Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 5.72 shares of worth $21.08 million or 0.82% of the total outstanding shares. The later fund manager was in possession of 4.98 shares on Nov 30, 2024, making its stake of worth around $18.33 million in the company or a holder of 0.71% of company’s stock.
